The hypolipidemic effects of high-dose statines in the treatment of the acute coronary syndrom

Giliarevskiĭ S.R.; Orlov V.A.; Kuz'mina I.M.; Baturina O.V.

doi:https://doi.org/

Giliarevskiĭ S.R.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo;
kafedra klinicheskoĭ farmakologii i terapii RMAPO

Orlov V.A.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo;
kafedra klinicheskoĭ farmakologii i terapii RMAPO

Kuz'mina I.M.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo;
kafedra klinicheskoĭ farmakologii i terapii RMAPO

Baturina O.V.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo;
kafedra klinicheskoĭ farmakologii i terapii RMAPO

The hypolipidemic effects of high-dose statines in the treatment of the acute coronary syndrom

Authors:

Giliarevskiĭ S.R., Orlov V.A., Kuz'mina I.M., Baturina O.V.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2012;5(4): 36‑41

Read: 786 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Giliarevskiĭ SR, Orlov VA, Kuz'mina IM, Baturina OV. The hypolipidemic effects of high-dose statines in the treatment of the acute coronary syndrom. Russian Journal of Cardiology and Cardiovascular Surgery. 2012;5(4):36‑41. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

Anderson J.L., Adams C.D., Antman E.M. et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation 2007; 116: Suppl: 148-304.
Antman E.M., Anbe D.T., Armstrong P.W. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
Hulten E., Jackson J.L., Douglas K. et al. The effect of early, intensive statin therapy on acute coronary syndrome: a metaanalysis of randomized controlled trials. Arch Intern Med 2006; 166: 1814-1821.
Shimojima M., Kawashiri M.A., Nitta Y. et al. Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography. Am J Cardiovasc Dis 2012; 2: 84-88.
Jones P.H., Davidson M.H., Stein E.A. et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-160.
Faergeman O., Hill L., Windler E. et al.; on behalf of the ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 2008; 111: 219-228.
Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010; 105: 69-76.
Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
Pitt B., Loscalzo J., Monyak J. et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol 2012; 109: 1239-1246.
Pedersen T.R., Faergeman O., Kastelein J.J. et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-2445.
Ridker P.M., Morrow D.A., Rose L.M. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol 70 mg/dl and C-reactive protein 2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005; 45: 1644-1648.
Murphy S.A., Cannon C.P., Wiviott S.D. et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009; 54: 2358-2362.
Tikkanen M.J., Szarek M., Fayyad R. et al. IDEAL Investigators. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009; 54: 2353-2357.
Nicholls S.J., Ballantyne C.M., Barter P.J. et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-2087.
Morrissey R.P., Diamond G.A., Kaul S. Statins in acute coronary syndromes. Do the guideline recommendations match the evidence? J Am Coll Cardiol 2009; 54: 425-433.
de Lemos J.A., Blazing M.A., Wiviott S.D. et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
Armitage J., Bowman L., Wallendszus K. et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376: 1658-1669.
Cannon C.P., Braunwald E., McCabe C.H. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
Yusuf S., Islam S., Chow C.K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231-1243.
Haas J.S., Phillips K.A., Gerstenberger E.P., Seger A.C. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med 2005; 142: 891-897.
Vale N., Nordmann A.J. Schwartz G.G. et al. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2011; CD006870.pub2.